Journal of cardiac failure · 2021
Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy.
СтатьяConsensus StatementНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Seferović Petar M, Tsutsui Hiroyuki, Mcnamara Dennis M, Ristić Arsen D, Basso Cristina, Bozkurt Biykem, Cooper Leslie T, Filippatos Gerasimos, Ide Tomomi, Inomata Takayuki, Klingel Karin, Linhart Aleš, Lyon Alexander R, Mehra Mandeep R, Polovina Marija, Milinković Ivan, Nakamura Kazufumi, Anker Stefan D, Veljić Ivana, Ohtani Tomohito, Okumura Takahiro, Thum Thomas, Tschöpe Carsten, Rosano Giuseppe, Coats Andrew J S, Starling Randall C
Аннотация
Endomyocardial biopsy (EMB) is an invasive procedure, globally most often used for the monitoring of heart transplant rejection. In addition, EMB can have an important complementary role to the clinical assessment in establishing the diagnosis of diverse cardiac disorders, including myocarditis, cardiomyopathies, drug-related cardiotoxicity, amyloidosis, other infiltrative and storage disorders, and cardiac tumors. Improvements in EMB equipment and the development of new techniques for the analysis of EMB samples has significantly improved the diagnostic precision of EMB. The present document is the result of the Trilateral Cooperation Project between the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America, and the Japanese Heart Failure Society. It represents an expert consensus aiming to provide a comprehensive, up-to-date perspective on EMB, with a focus on the following main issues: (1) an overview of the practical approach to EMB, (2) an update on indications for EMB, (3) a revised plan for heart transplant rejection surveillance, (4) the impact of multimodality imaging on EMB, and (5) the current clinical practice in the worldwide use of EMB.